Expanded Label For Sanofi Pasteur's Menactra May Lead To Only Limited Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended approval of the meningococcal disease vaccine to children as young as nine months, but if the CDC recommends it only for high-risk groups the expanded market could be limited.
You may also be interested in...
Novartis’ Expansion Of Menveo Further Set Back By “Complete Response”
FDA issues “complete response” for an sBLA that would expand use of Novartis’ meningitis vaccine in children aged two months to 24 months, which could have offered a competitive advantage against Sanofi’s market-leading Menactra.
Menveo Ad Should Not List CDC Recommendations Because It Does Not Meet Them, FDA Says
The approved use of Novartis' meningococcal disease vaccine does not match up with CDC recommendations, FDA says in a letter to the company.
Menveo Ad Should Not List CDC Recommendations Because It Does Not Meet Them, FDA Says
The approved use of Novartis' meningococcal disease vaccine does not match up with CDC recommendations, FDA says in a letter to the company.